Brian Krob is a partner in Nixon Peabody's Corporate practice group. He represents corporate acquirers as well as private equity firms in their acquisitions and dispositions, with a focus on health care and technology.
I represent for-profit and nonprofit health care clients in a wide variety of transactions. For hospitals and health systems, I advise on mergers and complex joint ventures. Physician groups turn to me for assistance with forming integrated physician networks, and representing those networks in acquisitions and sales. I also represent investors and physicians forming and investing in surgery centers, and growth equity investors in their investments and dispositions of health care portfolios.
Throughout my career I’ve represented private equity funds in the acquisition and disposition of their portfolio companies. While a company is being held by a private equity fund, I work with management to resolve their day-to-day legal issues, with an ultimate goal of positioning the company for disposition by the fund.
Complexity in transactions will continue to rise. Almost all transactions now have international elements to them, whether representing an entity with foreign operations, a U.S. business seeking to make an acquisition abroad or a foreign investor seeking to deploy capital in the U.S. All of this is in a rising tide of uncertainty. Excellent counsel can provide practical legal strategies for managing these complexities.
Law360 | May 10, 2019
Boston Corporate partner David Martland and Chicago Corporate partner Brian Krob are mentioned in this roundup of notable deals for advising Merck in its acquisition of Intermolecular.
University of Illinois College of Law, J.D., magna cum laude, Order of the Coif
University of Kansas, B.A., with honors
Brian has been recommended in The Legal 500 United States 2021 editorial for M&A/Corporate and commercial—M&A: Middle-market (sub-$500m).He has also been recognized in previous years.